FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885221453> ?p ?o ?g. }

• W2885221453 abstract "Tumors evade immune surveillance using several mechanisms such as induction of regulatory T-cells (Tregs) and upregulation of indolemine-2,3-dioxygenase (IDO) enzyme. IDO is an intracellular enzyme that mediates its immunosuppressive effects by depleting tryptophan leading to accumulation of kynurenine and in turn reducing the proliferation of effector cells while activating Tregs. IDO is expressed by several suppressive immune cells including Tregs, suppressive antigen presenting cells (APCs), as well as by tumor cells. These immunosuppressive effects of IDO make it an attractive target for cancer immunotherapy, including a target for vaccine therapy. To test the anti-tumor immune effect of IDO vaccine, we evaluated the anti-tumor effect of an IDO-derived MHC I restricted peptide (IDO-pep) vaccine in the low IDO-expressing (TC-1) and high IDO-expressing B16 (melanoma) mouse tumor models. For this, mice were treated with three doses of IDO-peptides in combination with the respective tumor-specific vaccines (E7 for TC-1 and gp100 for B16) at an interval of seven days, followed by assessment of tumor growth and mice survival. We observed a significant delay in the tumor growth and prolonged survival in both tumor models when IDO vaccine was combined with tumor-specific antigen vaccine. We found that tumor-infiltration of antigen-specific CD8+ T-cells was significantly enhanced following the addition of IDO vaccine. Furthermore, while CD4+ T-cells increased in the tumor microenvironment (TME), there was a significant reduction in the numbers of Treg cells. We also found a significant reduction in the numbers of IDO-expressing myeloid-derived suppressor cells (MDSCs), dendritic cells as well as macrophages out of the total CD45+CD11b+ myeloid cells in the TME after the administration of IDO-pep in combination with tumor antigen-specific vaccine. In conclusion, our findings suggest that IDO-pep vaccine enhances the specific anti-tumor immune response by increasing the tumor antigen-specific effector T-cell infiltration in the TME through inhibition of immune suppressive cells. These results also suggest that MHC I restricted IDO peptide treatment is a promising strategy to improve cancer immunotherapy. Citation Format: Rahul Nandre, Vivek Verma, Pankaj Gaur, Pooja Vir, Hua Wang, Baolin Kang, Ayako Wakatsuki Pedersen, Mai-Britt Zocca, Mads Hald Andersen, Seema Gupta, Samir Khleif. IDO vaccine enhances antigen-specific anti-tumor effects by reducing IDO-expressing antigen presenting cells and MDSCs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3763." @default.
• W2885221453 created "2018-08-22" @default.
• W2885221453 creator A5008904835 @default.
• W2885221453 creator A5013484739 @default.
• W2885221453 creator A5015839480 @default.
• W2885221453 creator A5017721294 @default.
• W2885221453 creator A5021651059 @default.
• W2885221453 creator A5026861780 @default.
• W2885221453 creator A5048143305 @default.
• W2885221453 creator A5058608864 @default.
• W2885221453 creator A5060519673 @default.
• W2885221453 creator A5074265217 @default.
• W2885221453 creator A5086026022 @default.
• W2885221453 date "2018-07-01" @default.
• W2885221453 modified "2023-10-16" @default.
• W2885221453 title "Abstract 3763: IDO vaccine enhances antigen-specific anti-tumor effects by reducing IDO-expressing antigen presenting cells and MDSCs" @default.
• W2885221453 doi "https://doi.org/10.1158/1538-7445.am2018-3763" @default.
• W2885221453 hasPublicationYear "2018" @default.
• W2885221453 type Work @default.
• W2885221453 sameAs 2885221453 @default.
• W2885221453 citedByCount "0" @default.
• W2885221453 crossrefType "proceedings-article" @default.
• W2885221453 hasAuthorship W2885221453A5008904835 @default.
• W2885221453 hasAuthorship W2885221453A5013484739 @default.
• W2885221453 hasAuthorship W2885221453A5015839480 @default.
• W2885221453 hasAuthorship W2885221453A5017721294 @default.
• W2885221453 hasAuthorship W2885221453A5021651059 @default.
• W2885221453 hasAuthorship W2885221453A5026861780 @default.
• W2885221453 hasAuthorship W2885221453A5048143305 @default.
• W2885221453 hasAuthorship W2885221453A5058608864 @default.
• W2885221453 hasAuthorship W2885221453A5060519673 @default.
• W2885221453 hasAuthorship W2885221453A5074265217 @default.
• W2885221453 hasAuthorship W2885221453A5086026022 @default.
• W2885221453 hasConcept C147483822 @default.
• W2885221453 hasConcept C154317977 @default.
• W2885221453 hasConcept C167672396 @default.
• W2885221453 hasConcept C202751555 @default.
• W2885221453 hasConcept C203014093 @default.
• W2885221453 hasConcept C2776107976 @default.
• W2885221453 hasConcept C2776662205 @default.
• W2885221453 hasConcept C2776706248 @default.
• W2885221453 hasConcept C2777701055 @default.
• W2885221453 hasConcept C2780674031 @default.
• W2885221453 hasConcept C502942594 @default.
• W2885221453 hasConcept C515207424 @default.
• W2885221453 hasConcept C55493867 @default.
• W2885221453 hasConcept C71924100 @default.
• W2885221453 hasConcept C83478079 @default.
• W2885221453 hasConcept C86803240 @default.
• W2885221453 hasConcept C8891405 @default.
• W2885221453 hasConceptScore W2885221453C147483822 @default.
• W2885221453 hasConceptScore W2885221453C154317977 @default.
• W2885221453 hasConceptScore W2885221453C167672396 @default.
• W2885221453 hasConceptScore W2885221453C202751555 @default.
• W2885221453 hasConceptScore W2885221453C203014093 @default.
• W2885221453 hasConceptScore W2885221453C2776107976 @default.
• W2885221453 hasConceptScore W2885221453C2776662205 @default.
• W2885221453 hasConceptScore W2885221453C2776706248 @default.
• W2885221453 hasConceptScore W2885221453C2777701055 @default.
• W2885221453 hasConceptScore W2885221453C2780674031 @default.
• W2885221453 hasConceptScore W2885221453C502942594 @default.
• W2885221453 hasConceptScore W2885221453C515207424 @default.
• W2885221453 hasConceptScore W2885221453C55493867 @default.
• W2885221453 hasConceptScore W2885221453C71924100 @default.
• W2885221453 hasConceptScore W2885221453C83478079 @default.
• W2885221453 hasConceptScore W2885221453C86803240 @default.
• W2885221453 hasConceptScore W2885221453C8891405 @default.
• W2885221453 hasLocation W28852214531 @default.
• W2885221453 hasOpenAccess W2885221453 @default.
• W2885221453 hasPrimaryLocation W28852214531 @default.
• W2885221453 hasRelatedWork W1969071717 @default.
• W2885221453 hasRelatedWork W2055759108 @default.
• W2885221453 hasRelatedWork W2077965685 @default.
• W2885221453 hasRelatedWork W2888292469 @default.
• W2885221453 hasRelatedWork W2895277028 @default.
• W2885221453 hasRelatedWork W3081262846 @default.
• W2885221453 hasRelatedWork W3172495772 @default.
• W2885221453 hasRelatedWork W3185001536 @default.
• W2885221453 hasRelatedWork W4220661914 @default.
• W2885221453 hasRelatedWork W4283369204 @default.
• W2885221453 isParatext "false" @default.
• W2885221453 isRetracted "false" @default.
• W2885221453 magId "2885221453" @default.
• W2885221453 workType "article" @default.